Purpose | Board Meetings Date | Announcement Date |
---|---|---|
Board Meeting | 2 Aug 2025 | 28 Jul 2025 |
Epigral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2025 inter alia to consider and approve Un-audited Financial Results for the Quarter Ended 30th June 2025 and evaluate proposal for raising of funds. UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ONN30.06.2025. (As Per BSE Announcement Dated on: 02.08.2025) | ||
Board Meeting | 5 May 2025 | 23 Apr 2025 |
Epigral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2025 inter alia to consider and approve Audited Financial Results and recommendation of Final Dividend if any. Outcome of Board Meeting held on Monday, 5th May, 2025 and submission of Audited Financial Results (Standalone & Consolidated) for the Fourth Quarter and year ended on 31st March, 2025 & Declared Final dividend of Rs.3.50 (35%) per Equity Share of face value of Rs. 10/- each for the Financial Year 2024-25. (As Per BSE Announcement Dated on 05.05.2025) | ||
Board Meeting | 27 Jan 2025 | 18 Jan 2025 |
Epigral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 inter alia to consider and approve Un-Audited Financial Results for the Third Quarter and Nine Months ended on 31st December 2024 and to declare Interim Dividend on the equity shares of the Company for the Financial Year 2024-25. Outcome of Board Meeting held on Monday, 27th January, 2025 containing submission of Un-Audited Financial Results (Standalone & Consolidated) for the Third Quarter and Nine Months ended on 31st December, 2024 and Declaration of interim dividend of Rs. 2.50 (25%) per Equity Share of face value of Rs. 10/- each for the Financial Year 2024-25. (As Per BSE Announcement Dated on 27/01/2025) | ||
Board Meeting | 9 Nov 2024 | 29 Oct 2024 |
Quarterly Results Outcome of Board Meeting held on Saturday, 9th November, 2024 and submission of Un-Audited Financial Results (Standalone & Consolidated) for the Second Quarter and Half Year ended on 30th September, 2024. UFR - 30.09.2024 Expansion of production capacity of CPVC and Epichlorohydrin at Dahej, Gujarat. (As Per BSE Announcement Dated on 09.11.2024) |
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.